

In the Supreme Court of the United States

AETNA HEALTH INC., FKA AETNA U.S. HEALTHCARE
INC. AND AETNA U.S. HEALTHCARE OF
NORTH TEXAS INC., PETITIONER

v.

JUAN DAVILA

CIGNA HEALTHCARE OF TEXAS, INC., DBA CIGNA
CORPORATION, PETITIONER

v.

RUBY R. CALAD, ET AL.

*ON WRITS OF CERTIORARI
TO THE UNITED STATES COURT OF APPEALS
FOR THE FIFTH CIRCUIT*

**BRIEF FOR THE UNITED STATES AS
AMICUS CURIAE SUPPORTING PETITIONERS**

HOWARD M. RADZELY
Solicitor of Labor
ALLEN H. FELDMAN
Associate Solicitor
NATHANIEL I. SPILLER
Deputy Associate Solicitor
EDWARD D. SIEGER
Attorney
Department of Labor
Washington, D.C. 20210

PAUL D. CLEMENT
Acting Solicitor General
Counsel of Record
EDWIN S. KNEEDLER
Deputy Solicitor General
JAMES A. FELDMAN
Assistant to the Solicitor
General
Department of Justice
Washington, D.C. 20530-0001
(202) 514-2217

QUESTION PRESENTED

Under *Metropolitan Life Insurance Co. v. Taylor*, 481 U.S. 58 (1987), certain state-law claims can be removed from state to federal court if they fall within the scope of the civil enforcement provisions of the Employee Retirement Income Security Act of 1974 (ERISA), 29 U.S.C. 1132(a), and are thereby “completely preempted.” The question presented is whether ERISA completely preempts state-law claims by an ERISA plan participant or beneficiary against a health maintenance organization (HMO) where the claims challenge an HMO’s decision to deny coverage of treatment or care that was prescribed by the claimant’s physician but that the HMO decided was not authorized under the plan’s “medical necessity” proviso.

TABLE OF CONTENTS

	Page
Interest of the United States	1
Statement:	2
1. <i>Aenta Health Inc. v. Davila</i>	2
2. <i>Cigna HealthCare of Texas, Inc. v. Calad</i>	4
3. The court of appeals' decision	5
Summary of argument	6
Argument:	
ERISA completely preempts respondents' state-law claims because they fall within the scope of Section 502(a)	9
A. State-law claims within the scope of Section 502(a) are removable from state to federal court	9
B. Respondent's claims fall within the scope of Section 502(a)(1)(B)	12
C. The fact that plaintiffs' actions are tort-based underscores their complete preemption	17
D. <i>Pegram v. Herdrich</i> does not bar complete preemption of respondents' claims	21
E. Complete preemption effectuates the congressional balance between providing prompt and appropriate remedies for claimants and encouraging the formation and growth of employee benefit plans	25
Conclusion	28

TABLE OF AUTHORITIES

Cases:	
<i>Allis-Chalmers Corp. v. Lueck</i> , 471 U.S. 202 (1985)	19
<i>Beneficial Nat'l Bank v. Anderson</i> , 123 S. Ct. 2058 (2003)	9, 10, 15

IV

Cases—Continued:	Page
<i>Black & Decker Disability Plan v. Nord</i> , 538 U.S. 822 (2003)	27
<i>Bowerman v. Wal-Mart Stores, Inc.</i> , 226 F.3d 574 (7th Cir. 2000)	28
<i>Caterpillar Inc. v. Williams</i> , 482 U.S. 386 (1987)	10
<i>Cicio v. Does</i> , 321 F.3d 83 (2d Cir.), petition for cert. filed, No. 03-69 (July 11, 2003)	21
<i>Dardinger v. Anthem Blue Cross & Blue Shield</i> , 781 N.E.2d 121 (Ohio 2002)	30
<i>Franchise Tax Bd. v. Construction Laborers Vacation Trust</i> , 463 U.S. 1 (1983)	12
<i>Great-West Life & Annuity Ins. Co. v. Knudson</i> , 534 U.S. 204 (2002)	27
<i>Healthcare Inc., In re</i> , 193 F.3d 151 (3d Cir. 1999), cert. denied, 530 U.S. 1242 (2000)	29
<i>Heasley v. Belden & Blake Corp.</i> , 2 F.3d 1249 (3d Cir. 1993)	16
<i>Ingersoll-Rand Co. v. McClendon</i> , 498 U.S. 133 (1990)	7, 11, 18, 26, 29
<i>Kekis v. Blue Cross & Blue Shield of Utica-Watertown, Inc.</i> , 815 F. Supp. 571 (N.D.N.Y. 1993)	16
<i>Kopicki v. Fitzgerald Auto. Family Employee Benefits Plan</i> , 121 F. Supp. 2d 467 (D. Md. 2000)	16
<i>Kulakowski v. Rochester Hosp. Serv. Corp.</i> , 779 F. Supp. 710 (W.D.N.Y. 1991)	16-17
<i>Lockheed Corp. v. Spink</i> , 517 U.S. 882 (1996)	26
<i>Marro v. K-III Communications Corp.</i> , 943 F. Supp. 247 (E.D.N.Y. 1996)	16
<i>Massachusetts Mut. Life Ins. Co. v. Russell</i> , 473 U.S. 134 (1985)	21
<i>Mattive v. Healthsource of Savannah, Inc.</i> , 893 F. Supp. 1559 (S.D. Ga. 1995)	16
<i>Mertens v. Hewitt Assocs.</i> , 508 U.S. 248 (1993)	27
<i>Metropolitan Life Ins. Co. v. Taylor</i> , 481 U.S. 58 (1987)	4, 6, 10, 11, 12, 13, 15, 18, 20

Cases—Continued:	Page
<i>Pegram v. Herdrich</i> , 530 U.S. 211 (2000)	8, 21, 22, 23, 24
<i>Pilot Life Ins. Co. v. Dedeaux</i> , 481 U.S. 41 (1987)	<i>passim</i>
<i>Pryzbowski v. U.S. Healthcare, Inc.</i> , 245 F.3d 266 (3d Cir. 2001)	16, 28, 29
<i>Rush Prudential HMO, Inc. v. Moran</i> , 536 U.S. 355 (2002)	8, 12, 18, 19, 20, 21, 23, 28
<i>Shannon v. Jack Eckerd Corp.</i> , 113 F.3d 208 (11th Cir. 1997), cert. denied, 522 U.S. 1111 (1998)	17
<i>Shaw v. Delta Air Lines, Inc.</i> , 463 U.S. 85 (1983)	26
<i>Strom v. Goldman Sach & Co.</i> , 202 F.3d 138 (2d Cir. 1999)	28
<i>UNUM Life Ins. Co. v. Ward</i> , 526 U.S. 358 (1999)	12
<i>U.S. Healthcare, Inc., In re</i> , 193 F.3d 151 (3d Cir. 1999), cert. denied, 530 U.S. 1242 (2000)	29
<i>Variety Corp. v. Howe</i> , 516 U.S. 489 (1996)	17, 24-25, 27
<i>Villazon v. Prudential Health Care Plan, Inc.</i> , 843 So. 2d 842 (Fla. 2003)	29
<i>White v. Caterpillar, Inc.</i> , 765 F. Supp. 1418 (W.D. Mo.), aff'd, 985 F.2d 564 (8th Cir. 1991)	17, 27
<i>Wilson v. Group Hospitalization & Med. Servs., Inc.</i> , 791 F. Supp. 309 (D.D.C. 1992), appeal dismissed, 995 F.2d 306 (D.C. Cir. 1993)	16, 27
Statutes and regulations:	
Employee Retirement Income Security Act of 1974, Tit. I, 29 U.S.C. 1001 <i>et seq.</i>	6
29 U.S.C. 1001(b)	26
29 U.S.C. 1002(13)	1
29 U.S.C. 1002(21)(A)(iii)	24
29 U.S.C. 1109 (§ 409)	21
29 U.S.C. 1109(a)	21
29 U.S.C. 1132(a) (§ 502(a))	1, 4, 7, 8, 10, 12, 13, 26
29 U.S.C. 1132(a)(1)(B) (§ 502(a)(1)(B))	<i>passim</i>

VI

Statutes and regulations—Continued:	Page
29 U.S.C. 1132(a)(2) (§ 502(a)(2))	6, 21
29 U.S.C. 1132(a)(3) (§ 502(a)(3))	5, 17, 20, 27
29 U.S.C. 1132(g)	27
29 U.S.C. 1133 (§ 503)	9, 28
29 U.S.C. 1133(1)	26
29 U.S.C. 1133(2) (§ 503(2))	24, 25, 26
29 U.S.C. 1136(b)	1
29 U.S.C. 1144(a) (§ 514(a))	12, 14
29 U.S.C. 1144(b)(2)(A)	12
29 U.S.C. 1185(a)	26
28 U.S.C. 1441(b)	9-10
Texas Health Care Liability Act, Tex. Civ. Prac. & Rem. Code Ann. (West Supp. 2004):	
§§ 88.001 <i>et seq.</i>	3
§ 88.001(5)	3
§ 88.002(a)	3
§ 88.002(c)	3
29 C.F.R.:	
Section 2560.503-1(f)(2)(i)	28
Section 2560.503-1(f)(2)(iii)(A)	28
Section 2560.503-1(g)(1) (2000)	25
Section 2560.503-1(g)(1)(i)	26, 28
Section 2560.503-1(h)(1)	25, 26
Section 2560.503-1(h)(2)(iv)	26
Section 2560.503-1(h)(3)(ii)	25
Section 2560.503-1(i)(1)(ii)	25
Section 2560.503-1(j)(1)	26
Section 2560.503-1(j)(5)(ii)	26
Miscellaneous:	
Gail B. Agrawal & Mark A. Hall, <i>What If You Could See Your HMO? Managed Care Liability Beyond the ERISA Shield</i> , 47 St. Louis U.L.J. 235 (2003)	29, 30
George G. Bogert & George T. Bogert, <i>The Law of Trusts and Trustees</i> (rev. 2d ed. 1995)	28

VII

Miscellaneous—Continued:	Page
66 Fed. Reg. 35,886 (2001)	28
Restatement (Second) of the Law of Trusts (1959)	28
United States General Accounting Office, <i>Employer- Based Managed Care Plans: ERISA's Effect on Remedies for Benefit Denials and Medical Mal- practice</i> (July 1998) (GAO/HEHS-98-154)	17, 24, 29

In the Supreme Court of the United States

No. 02-1845

AETNA HEALTH INC., FKA AETNA U.S. HEALTHCARE
INC. AND AETNA U.S. HEALTHCARE OF
NORTH TEXAS INC., PETITIONER

v.

JUAN DAVILA

No. 03-83

CIGNA HEALTHCARE OF TEXAS, INC., DBA CIGNA
CORPORATION, PETITIONER

v.

RUBY R. CALAD, ET AL.

*ON WRITS OF CERTIORARI
TO THE UNITED STATES COURT OF APPEALS
FOR THE FIFTH CIRCUIT*

**BRIEF FOR THE UNITED STATES AS
AMICUS CURIAE SUPPORTING PETITIONERS**

INTEREST OF THE UNITED STATES

This case concerns the scope of “complete preemption” under Section 502(a) of the Employee Retirement Income Security Act of 1974 (ERISA), 29 U.S.C. 1132(a), as applied to state-law claims against a health maintenance organization (HMO). Because the Secretary of Labor has primary authority for enforcing and administering Title I of ERISA, see 29 U.S.C. 1002(13), 1136(b), which includes Section 502(a), the United States has a substantial interest in

ensuring that ERISA's complete preemption principle is appropriately applied.

STATEMENT

1. *Aetna Health Inc. v. Davila*

a. Petitioner Aetna Health Inc.'s predecessors provided HMO coverage to respondent Juan Davila pursuant to an ERISA plan sponsored by Davila's employer. 02-1845 Pet. App. 4a, 67a. The agreement between Aetna and the employer provided that Aetna would contract with participating physicians who were independent contractors and solely responsible for health services rendered to covered patients. *Id.* at 98a. The agreement gave Aetna "complete authority to review all claims for Covered Benefits," including "discretionary authority to determine whether and to what extent eligible individuals and beneficiaries are entitled to coverage and construe any disputed or doubtful terms under th[e] Group Agreement." *Id.* at 102a.

The agreement required benefits to be "[m]edically [n]ecessary" to be covered and specified that "[f]or the purpose of coverage, [Aetna] may determine whether any benefit provided under the [Certificate of Coverage] is [m]edically [n]ecessary." 02-1845 Pet. App. 122a. Among other things, "medically necessary" means that a service or supply "must * * * be no more costly * * * than any equally effective service or supply" in satisfying certain standards of medical efficacy. *Id.* at 122a-123a. The agreement provided that its coverage "does not restrict a Member's ability to receive health care benefits that are not, or might not be, [c]overed [b]enefits." *Id.* at 177a.

b. In April 2000, Davila's primary care physician prescribed Vioxx for Davila's arthritis. 02-1845 Pet. App. 67a, 76a. Aetna refused to pay for the prescription, which led the physician to contact Aetna concerning the refusal. *Id.* at 77a. In May 2000, an Aetna representative informed the physi-

cian that, under its formulary policy, Aetna would approve Vioxx only if Davila “has a diagnosis of osteoarthritis or acute pain and has a contraindication, intolerance, allergy to or a documented adequate trial” of at least two other covered drugs. *Id.* at 80a; see *id.* at 4a, 67a-68a. Davila began taking one of those other drugs (a generic drug, naprosyn), which allegedly led to a hospitalization for bleeding ulcers, a near-heart attack, and internal bleeding. *Id.* at 5a, 68a, 77a.

After his hospitalization, Davila sued Aetna in Texas state court for violations of the Texas Health Care Liability Act (THCLA), Tex. Civ. Prac. & Rem. Code Ann. §§ 88.001 *et seq.* (West Supp. 2004) (reproduced at 02-1485 Pet. App. 56a-63a). See *id.* at 68a-70a. The THCLA requires a health insurance carrier, HMO, or other managed care entity “to exercise ordinary care when making health care treatment decisions” and imposes liability for damages for harm to an insured or enrollee proximately caused by its failure to exercise such care. Tex. Civ. Prac. & Rem. Code Ann. § 88.002(a) (West Supp. 2004). The THCLA defines “[h]ealth care treatment decision” to mean

a determination made when medical services are actually provided by the health care plan and a decision which affects the quality of the diagnosis, care, or treatment provided to the plan’s insureds or enrollees.

Id. § 88.001(5). It is a defense to an action asserted against an insurer, HMO, or other managed care entity that neither it nor any of its employees or agents “controlled, influenced, or participated in the health care treatment decision” and “did not deny or delay payment for any treatment prescribed or recommended by a provider to the insured or enrollee.” *Id.* § 88.002(c).

Davila alleged that Aetna’s adherence to its policies on the use of Vioxx amounted to a failure to use ordinary care in making a health care treatment decision that affected the

quality of the treatment Davila received. 02-1845 Pet. App. 68a-69a. He further alleged that Aetna was liable for punitive damages because Aetna knew its policy involved a risk of serious injury or death. *Id.* at 70a-71a.

c. Aetna removed the action to federal court based on the “complete preemption” doctrine recognized in *Metropolitan Life Insurance Co. v. Taylor*, 481 U.S. 58 (1987). 02-1845 Pet. App. 89a. Under that doctrine, a state-law claim that falls within the scope of the civil enforcement provisions in Section 502(a) of ERISA, 29 U.S.C. 1132(a), is deemed to be a federal claim subject to removal. *Taylor*, 481 U.S. at 65-67. Aetna argued that Davila’s state-law claims were within the scope of Section 502(a) because they were based on Aetna’s “allegedly wrongful conduct of denying benefits.” 02-1845 Pet. App. 87a.

Davila filed a motion to remand the case to state court, which the district court denied. 02-1845 Pet. App. 30a-35a. The district court reasoned that while ERISA would not completely preempt a claim challenging the quality of medical care a participant received, the claim here, “fairly construed, actually challenges the administration of health benefits under an ERISA plan.” *Id.* at 33a-34a. Because Davila chose not to refile his state-law claims as ERISA claims, the district court dismissed his state-law claims with prejudice. *Id.* at 34a-35a.

2. CIGNA HealthCare of Texas, Inc. v. Calad

a. Ruby Calad became a member of CIGNA HealthCare’s HMO through an ERISA plan provided by her husband’s employer. 03-83 Pet. App. 3a, 33a. Under the plan, hospital benefits would not be paid for any day in excess of the number of days certified through a pre-admission certification (PAC) or continued stay review (CSR). CIGNA Opp. Mot. Remand App. 22.

In September 1999, Calad was admitted to a hospital for a hysterectomy. Cause No. 00-09041 Pl. Orig. Pet. para. 4.

During pre-authorization procedures, CIGNA allegedly informed her that it authorized only one day of hospitalization following the surgery. 03-83 Pet. App. 34a. On the second day after surgery, a CIGNA representative allegedly informed Calad's treating physician that CIGNA would not extend her hospital stay unless she had hemorrhaging, fever, or high blood pressure; without those symptoms, Calad would have to pay the cost of an extended hospitalization. *Id.* at 34a-35a. Calad was discharged, but she suffered complications that caused her to return to the emergency room a few days later. *Id.* at 3a. Alleging that she did not qualify for a continued hospital stay under CIGNA's medical necessity criteria and was unable to pay for the hospitalization, she sued CIGNA in state court under the THCLA for failing to use ordinary care in its medical decisions. See *id.* at 3a, 30a, 35a.

CIGNA removed the action to federal court under the complete preemption doctrine. See 03-83 Pet. App. 30a-31a. The district court denied Calad's motion to remand and dismissed her state-law claims with prejudice because she chose not to amend her pleading to bring an ERISA claim. *Id.* at 40a.

3. *The court of appeals' decision*

The Fifth Circuit consolidated appeals by Davila and Calad and reversed the district courts' refusals to remand their claims to state court. 02-1845 Pet. App. 2a-3a. Removal of the claims by Davila and Calad was improper, the court held, because their claims were not covered by relevant provisions of Section 502(a) authorizing a suit for breach of fiduciary duty or a claim for benefits. *Id.* at 10a-20a.

In particular, the court concluded that respondents' claims were not within Section 502(a)(3) of ERISA, 29 U.S.C. 1132(a)(3), which authorizes suits to enjoin violations of ERISA or the plan or to obtain "other appropriate equitable

relief” to redress such violations or enforce ERISA or the plan, because respondents sought damages rather than equitable relief. 02-1845 Pet. App. 10a. The court also concluded that the claims were not within the scope of Section 502(a)(2) of ERISA, 29 U.S.C. 1132(a)(2), which authorizes a plan participant, beneficiary, or fiduciary or the Secretary to obtain “appropriate relief” for the plan against a fiduciary who breaches ERISA duties, because petitioners “were not acting as plan fiduciaries when denying [respondents] medical treatment.” 02-1845 Pet. App. 12a.

Finally, the court of appeals concluded that the claims by Davila and Calad did not fall within the scope of Section 502(a)(1)(B) of ERISA, 29 U.S.C. 1132(a)(1)(B), which allows a suit by a plan participant or beneficiary “to recover benefits due to him under the terms of his plan, to enforce his rights under the terms of the plan, or to clarify his rights to future benefits under the terms of the plan.” 29 U.S.C. 1132(a)(1)(B); see 02-1845 Pet. App. 15a-20a. The court reasoned that Section 502(a)(1)(B) “creates a cause of action for breach of contract,” which permits patients to obtain the benefits due “[w]hen a plan administrator incorrectly interprets the plan to deny benefits.” *Id.* at 16a. “[B]y contrast,” the court held, “[respondents] assert tort claims; they have not sued their ERISA plan administrator, nor do they challenge his interpretation of the plan.” *Ibid.*

SUMMARY OF ARGUMENT

A. The Employee Retirement Income Security Act of 1974, 29 U.S.C. 1001 *et seq.*, “completely preempts” respondents’ state-law claims. In *Pilot Life Insurance Co. v. Dedeaux*, 481 U.S. 41 (1987), the Court concluded that ERISA’s civil enforcement provisions provide an exclusive set of remedies and therefore preempt state-law claims that fall within the scope of those provisions. In *Metropolitan Life Insurance Co. v. Taylor*, 481 U.S. 58 (1987), decided the same day as *Pilot Life*, the Court held that such state-law

claims are “completely preempted”—*i.e.*, are removable from state to federal court as a jurisdictional matter and preempted by federal law on the merits. “Complete preemption” reflects a Congressional intent for Section 502(a) to provide the exclusive remedies for claims that fall within the scope of that section.

B. Respondents’ state-law claims are completely preempted because they fall within the scope of Section 502(a)(1)(B) of ERISA, 29 U.S.C. 1132(a)(1)(B). That provision affords plan participants and beneficiaries a cause of action to obtain benefits or enforce rights under an ERISA plan. The state-law claims in these cases clearly attempt to enforce rights under an ERISA plan, because petitioners’ liability is dependent on a showing that respondents were entitled to have petitioners pay for benefits under the plans. Because respondents’ state-law claims thus fall within the scope of Section 502(a)(1)(B) of ERISA, they are subject to complete preemption, and the federal courts accordingly had removal jurisdiction over these cases.

C. The court of appeals held that respondents’ claims are not completely preempted because they sound in tort, while Section 502(a)(1)(B), in the court’s view, creates a cause of action for breach of contract. That distinction is untenable; this Court has repeatedly held—in *Pilot Life*, in *Taylor*, and in *Ingersoll-Rand Co. v. McClendon*, 498 U.S. 133 (1990)—that tort-based claims are preempted or completely preempted by ERISA’s civil enforcement provisions in Section 502(a). The Court has never suggested that preemption under Section 502(a) depends on the categorization of a claim as contract-based or tort-based. To the contrary, the Court has stated that Section 502(a) provides exclusive remedies; the fact that a plaintiff seeks tort-type remedies or other remedies not authorized in Section 502(a) only reinforces the conclusion that the plaintiff’s claim is preempted or completely preempted. Although the court of appeals purported

to find support for its view in *Rush Prudential HMO, Inc. v. Moran*, 536 U.S. 355 (2002), that case supports and reaffirms the conclusion that state-law claims seeking remedies not authorized by Section 502(a) of ERISA are preempted under the principles of *Pilot Life, Taylor*, and *Ingersoll-Rand*.

D. *Pegram v. Herdrich*, 530 U.S. 211 (2000), does not alter that conclusion. In *Pegram*, the Court held that an HMO physician, who was both treating the patient and deciding whether treatment was covered by a plan, was not acting as an ERISA fiduciary when she made a “mixed” eligibility and treatment decision. *Pegram’s* conclusion about the existence of a fiduciary duty under ERISA, however, has little to do with whether respondents’ claims fall within the scope of a Section 502(a)(1)(B) claim for benefits. Moreover, *Pegram’s* holding that a physician making a medical necessity determination is not an ERISA fiduciary is properly limited to cases, such as *Pegram* itself, in which the physician is a treating physician serving simultaneously in a medical-treatment and benefits-determination role. ERISA and the governing regulations of the Secretary of Labor make clear that where, as here, the HMO and its representatives are not treating the patient but are making benefits determinations under an ERISA plan, they may serve in an ERISA fiduciary capacity.

E. ERISA is designed to provide participants and beneficiaries with the benefits promised by their plans and other appropriate equitable relief. While the remedies available under Section 502(a) of ERISA are not as broad as the tort remedies and punitive damages sought by respondents, ERISA’s civil enforcement scheme—which the complete preemption doctrine makes exclusive—nonetheless effectuates the congressional balance between providing prompt and appropriate remedies for claimants and encouraging the formation and growth of employee benefit plans. The ERISA regime protects claimants and permits remedies

that are effective for most claimants, including an injunction ordering an HMO to pay for proposed treatment before it is provided, appropriate equitable relief to redress violations of ERISA or an ERISA plan, important procedural protections under the recently revised claims regulations promulgated by the Department of Labor pursuant to Section 503 of the Act, 29 U.S.C. 1133, independent review of HMO medical-necessity decisions if state law so provides, and a possible state-court suit against a treating physician for malpractice and against an HMO when it is vicariously liable for a treating physician's decisions. Permitting state-law damage actions concerning what are at bottom coverage disputes in addition to those protections and remedies under ERISA itself would undermine the exclusivity of the remedies ERISA does provide. It would also undermine the uniform administration of plans operating in more than one State. Moreover, by increasing costs through awards of or exposure to punitive damages and other state-law remedies in ways that cannot readily be predicted or budgeted, allowance of state-law damage actions against HMOs or other insurers for an allegedly wrongful denial of a claim for benefits could frustrate ERISA's goal of promoting the interests of employees in having their employers provide and maintain adequate health plans.

ARGUMENT

ERISA COMPLETELY PREEMPTS RESPONDENTS' STATE-LAW CLAIMS BECAUSE THEY FALL WITHIN THE SCOPE OF SECTION 502(a)

A. State-Law Claims Within The Scope Of Section 502(a) Are Removable From State To Federal Court

1. Under 28 U.S.C. 1441(b), “[a] civil action filed in a state court may be removed to federal court if the claim is one ‘arising under’ federal law.” *Beneficial Nat’l Bank v. Anderson*, 123 S. Ct. 2058, 2062 (2003). Ordinarily, Section

1441(b) authorizes removal only when the federal question appears on the face of a well-pleaded complaint, but not when preemption is simply raised as a federal defense to a plaintiff's suit. *Metropolitan Life Ins. Co. v. Taylor*, 481 U.S. 58, 63 (1987). But certain statutes so completely occupy an area Congress has chosen to regulate exclusively as federal law, with a federal cause of action, "that any civil complaint raising this select group of claims is necessarily federal in character." *Taylor*, 481 U.S. at 63-64. With respect to those statutes, a claim that on its face raises only state-law claims but that also falls within the scope of the federal cause of action will be considered to raise the federal claim. See, e.g., *Beneficial Nat'l Bank*, 123 S. Ct. at 2063; *Caterpillar Inc. v. Williams*, 482 U.S. 386, 393 (1987); *Taylor*, 481 U.S. at 65.

2. ERISA's enforcement provisions have such a "complete preemption" effect. That conclusion follows from two basic premises. The first premise, established by *Pilot Life Insurance Co. v. Dedeaux*, 481 U.S. 41 (1987), is that ERISA's civil enforcement provisions—and, in particular, Section 502(a)(1)(B) of ERISA, 29 U.S.C. 1132(a)(1)(B)—provide an exclusive remedy; they therefore preempt any state-law claims that fall within their scope. The second premise, established by this Court's decision the same day in *Taylor*, is that the preemptive force of ERISA's civil enforcement provisions gives rise to complete preemption, and thus federal removal jurisdiction over claims that are pleaded under state law but that fall within the scope of Section 502(a).

a. In *Pilot Life*, an ERISA plan participant unsuccessfully sought disability benefits from the ERISA plan's insurer for a back injury at work. 481 U.S. at 43. The participant brought state-law tort and contract claims against the insurer in state court, seeking compensatory and punitive damages for the failure to provide benefits. *Id.* at 43-44.

This Court held that suits “asserting improper processing of claims under ERISA-regulated plans [are to] be treated as federal questions governed by § 502(a)” of ERISA, and are preempted. *Id.* at 56.

The Court’s conclusion in *Pilot Life* was based largely on its determination that “ERISA’s civil enforcement remedies were intended to be exclusive.” 481 U.S. at 54. ERISA’s civil enforcement scheme was carefully crafted by Congress, balancing “the need for prompt and fair claims settlement procedures against the public interest in encouraging the formation of employee benefit plans.” *Ibid.* The Court concluded that “[t]he policy choices reflected in the inclusion of certain remedies and the exclusion of others under the federal scheme would be completely undermined if ERISA-plan participants and beneficiaries were free to obtain remedies under state law that Congress rejected in ERISA.” *Ibid.* See also *Ingersoll-Rand Co. v. McClendon*, 498 U.S. 133, 145 (1990) (state-law cause of action preempted because it “purports to provide a remedy for the violation of a right * * * exclusively enforced by § 502(a)[3]”).

b. *Taylor* was decided the same day as *Pilot Life*. As in *Pilot Life*, an ERISA plan participant sought disability benefits for a back injury he had suffered at work. 481 U.S. at 61. As in *Pilot Life*, the insurer of the ERISA plan found that the plaintiff was not disabled and therefore not eligible for benefits. *Ibid.* Unlike in *Pilot Life*, the plaintiff brought suit in *state* court, asserting state-law “contract and tort” claims, *id.* at 62, and seeking both the disability benefits that he believed had been wrongfully denied and damages for his “mental anguish.” *Ibid.* The insurer removed the case to federal court.

This Court held that “this suit, though it purports to raise only state law claims, is necessarily federal in character by virtue of the clearly manifested intent of Congress,” and that it was accordingly “removable to federal court by the defen-

dants” under the complete preemption doctrine. *Taylor*, 481 U.S. at 67. The Court noted that its companion decision in *Pilot Life* held that “state common law causes of action asserting improper processing of a claim for benefits under an employee benefit plan regulated by [ERISA] are preempted by the Act.” *Id.* at 60. Although a mere preemption defense is not ordinarily a sufficient basis for removal jurisdiction, the Court explained that Congress had “clearly manifested an intent to make causes of action within the scope of the civil enforcement provisions of § 502(a) removable to federal court.” *Id.* at 66. Accordingly, the Court held that it was appropriate “to recharacterize a state law complaint displaced by § 502(a)(1)(B) as an action arising under federal law.” *Id.* at 64.¹

B. Respondents’ Claims Fall Within The Scope Of Section 502(a)(1)(B)

1. *Pilot Life* and *Taylor* establish that claims that fall within the scope of Section 502(a)(1)(B) are subject to complete preemption. In each of those cases, the plaintiffs could not have been successful on their contract and tort claims unless they could show that they were in fact entitled to have the defendants pay for benefits under their ERISA plans. In *Pilot Life*, for example, the plaintiff sought, *inter*

¹ In contrast to “complete preemption” of state causes of action that fall within the scope of Section 502(a) under *Taylor*, “ordinary” preemption of state law under Section 514(a) of ERISA, 29 U.S.C. 1144(a), does not by itself permit removal of a state-court action to federal court. *Taylor*, 481 U.S. at 64; *Franchise Tax Bd. v. Construction Laborers Vacation Trust*, 463 U.S. 1 (1983). A state law may be saved from “ordinary” preemption under ERISA’s insurance saving clause, see 29 U.S.C. 1144(b)(2)(A), even in a case in which the underlying claim is removable from state to federal court under the complete preemption doctrine. That would occur, for example, if the state law’s sole effect is to add a mandatory plan term that is enforceable only through an ERISA Section 502(a) action. See *Rush Prudential HMO, Inc. v. Moran*, 536 U.S. 355, 379-380 (2002); see also *UNUM Life Ins. Co. v. Ward*, 526 U.S. 358, 376-377 (1999).

alia, “[d]amages for failure to provide benefits under the insurance policy.” 481 U.S. at 43. In *Taylor*, the plaintiff sought, *inter alia*, “compensatory damages for money contractually owed Plaintiff.” 481 U.S. at 61. In both cases, the plaintiffs’ claims obviously could not have been successful if it were ultimately determined that they were not entitled to the benefits at issue.

Because the plaintiffs in *Pilot Life* and *Taylor* brought claims that depended on a showing that they were entitled to have the defendants pay for benefits under their ERISA plans, the Court had no difficulty in concluding in each case that the plaintiff’s claims fell within the scope of Section 502(a)(1)(B). Indeed, the showing of entitlement to payment that plaintiffs had to make in *Pilot Life* and *Taylor* was essentially the same showing that would have been required for them to bring a successful suit under Section 502(a)(1)(B), which creates a cause of action “to recover benefits due [a participant] under the terms of his plan” or “to enforce his rights under the terms of the plan.” 29 U.S.C. 1132(a)(1)(B). Accordingly, the state-law claims in those cases were squarely preempted.

2. Just as in *Pilot Life* and *Taylor*, respondents’ claims fall within the scope of Section 502(a)(1)(B) because they require adjudication of respondents’ entitlement to have petitioners pay for benefits under their ERISA plans. They also seek remedies additional to those provided under Section 502(a)(1)(B). They are therefore completely preempted.²

a. Respondent Davila’s state-law action alleges that Aetna, through its prescription drug formulary policies, “controlled, influenced, participated in and made decisions

² Because the state-law claims in these cases depend on a showing that respondents were entitled to benefits under their ERISA plans, these cases do not present the question whether a state-law claim that does not require adjudication of rights under an ERISA plan may nonetheless fall within the scope of Section 502(a) and therefore be completely preempted.

which affected the quality of the diagnosis, care, and treatment provided to” him; that Aetna thereby “violat[ed] the duty of ordinary care” set forth in Texas law; and that “[s]uch violation of ordinary care was the proximate cause of [Davila’s] damages.” 02-1845 Pet. App. 69a. In particular, Davila alleges that Aetna did not exercise due care when it concluded that he could not obtain Vioxx under the plan unless and until he had first tried other medications to treat his condition. *Id.* at 67a-69a.

As was true of the claims in *Pilot Life* and *Taylor*, Davila’s state-law claim necessarily requires adjudication of Davila’s right to obtain payment for Vioxx under his ERISA plan. Specifically, Davila’s claim requires a showing that Davila was entitled to payment for Vioxx either under the literal terms of the plan or under any provision of law incorporated into the plan—*i.e.*, any federal law applicable to the plan or any state law applicable to the plan that is not preempted (or saved from preemption) under Section 514(a). If he was not so entitled, then Aetna’s failure to pay for the drug was both justified and not the proximate cause of any injuries Davila suffered. In other words, Davila’s state-law claim depends on the showing that would have been necessary under Section 502(a)(1)(B) of ERISA “to recover benefits due to him under the terms of his plan” or “to enforce his rights under the terms of the plan.” 29 U.S.C. 1132(a)(1)(B).

Under the principles of *Pilot Life* and *Taylor*, claims like Davila’s that require a showing that the claimant could have recovered on a Section 502(a)(1)(B) claim are subject to complete preemption under ERISA. That is more, not less, clear when such state-law claims involve remedies not available under Section 502(a)(1)(B). Although Davila has purported to plead his claim under an alternative state-law cause of action that provides for remedies in addition to those available under ERISA, his claim nonetheless “is in

reality based on federal law” and is therefore completely preempted. *Beneficial Nat’l Bank*, 123 S. Ct. at 2063.

b. Similarly, Calad’s claim in No. 03-83 is completely preempted. The basis for her state-law complaint is an asserted right under her ERISA plan to obtain what she viewed as medically necessary treatment—in her case, more than one day of hospitalization after a hysterectomy, as recommended by her treating physician. Calad alleged that CIGNA interfered with that right by informing Calad and her treating physician that CIGNA would not pay for an extended hospital stay because she did not qualify under CIGNA’s medical necessity criteria for extended hospital coverage. 03-83 Pet. App. 34a-35a. If Calad did not have a legal right under her ERISA plan to payment for a medically necessary additional period in the hospital, then her state-law claim would fail. Accordingly, her state-law claim, like Davila’s, depends on a showing that she was entitled to payment under her ERISA plan for the additional medical treatment she sought. It follows that Calad’s complaint, like Davila’s, is subject to removal under the complete preemption doctrine.

c. These cases differ from *Pilot Life* and *Taylor* in that the benefits involved here are health care benefits, rather than disability benefits, and the defendants here are HMOs, rather than traditional insurers. Those facts, however, have no bearing on the analysis. Congress “expressed an intent that the civil enforcement provisions of ERISA § 502(a) be the exclusive vehicle for actions by ERISA-plan participants * * * asserting improper processing of a claim for benefits, and that varying state causes of action for claims within the scope of § 502(a) would pose an obstacle to the purposes and objectives of Congress.” *Pilot Life*, 481 U.S. at 52; see *Taylor*, 481 U.S. 63. That rationale applies regardless of whether the defendant is a traditional insurer making a post-treatment coverage decision under a fee-for-services plan (as in *Pilot Life* and *Taylor*) or an HMO making a pre-certifica-

tion coverage decision (as here), and regardless of whether the claims involve disability benefits (as in *Pilot Life* and *Taylor*) or medical benefits (as here). Accordingly, the rationale of *Pilot Life* and *Taylor* applies here, and respondents' claims are completely preempted.³

3. If any doubt remained as to whether respondents' state law claims fall within the scope of Section 502(a)(1)(B) of ERISA, the ability of claimants who are similarly situated to respondents to sue under ERISA confirms that respondents' claims are completely preempted. As the Third Circuit noted in holding that ERISA completely preempted a state-law claim against an HMO for denying treatment by an out-of-network provider, "[t]here have been numerous cases in which [federal] courts have issued preliminary injunctions under similar circumstances." *Pryzbowski v. U.S. Healthcare, Inc.*, 245 F.3d 266, 274 (3d Cir. 2001).⁴ There are also

³ By requiring that claims challenging HMO coverage decisions be brought under Section 502(a)(1)(B), the complete preemption doctrine ensures that ERISA standards—including the federal common law that Congress expected would apply to benefit claims, see *Pilot Life*, 481 U.S. at 56—will continue to apply to HMO coverage decisions in the same way they apply to coverage decisions by traditional insurers, such as Blue Cross and Blue Shield, and companies that administer self-insured plans. See, e.g., *Kopicki v. Fitzgerald Auto. Family Employee Benefits Plan*, 121 F. Supp. 2d 467, 470 (D. Md. 2000) (pre-treatment coverage decision by company administering self-insured plan); *Kekis v. Blue Cross & Blue Shield of Utica-Watertown, Inc.*, 815 F. Supp. 571, 573-576 (N.D.N.Y. 1993) (pre-treatment coverage decision by Blue Cross/Blue Shield).

⁴ See, e.g., *Heasley v. Belden & Blake Corp.*, 2 F.3d 1249, 1253 (3d Cir. 1993) (participant's challenge to administrator's decision not to pre-authorize liver transplant); *Kopicki v. Fitzgerald Auto. Family Employee Benefits Plan*, 121 F. Supp. 2d at 470-471 (beneficiary's challenge to administrator's decision not to pre-authorize stem cell treatment for cancer); *Marro v. K-III Communications Corp.*, 943 F. Supp. 247, 248-249 (E.D.N.Y. 1996) (similar); *Mattive v. Healthsource of Savannah, Inc.*, 893 F. Supp. 1559, 1562-1563 (S.D. Ga. 1995) (similar); *Kekis*, 815 F. Supp. at 576-577 (similar); *Wilson v. Group Hospitalization & Med. Servs., Inc.*, 791 F. Supp. 309, 310 (D.D.C. 1992) (similar), appeal dismissed, 995 F.2d 306 (D.C. Cir. 1993); *Kulakowski v. Rochester Hosp. Serv. Corp.*, 779 F. Supp.

cases in which a claimant obtains treatment recommended by a treating physician despite a refusal by a managed care entity to pay for it, and later challenges the HMO's denial of benefits under ERISA. See, e.g., *Shannon v. Jack Eckerd Corp.*, 113 F.3d 208, 209 (11th Cir. 1997), cert. denied, 522 U.S. 1111 (1998); United States General Accounting Office, *Employer-Based Managed Care Plans: ERISA's Effect on Remedies for Benefit Denials and Medical Malpractice* 12 (July 1998) (GAO/HEHS-98-154) (*GAO Report*) (“A health plan’s decision to deny coverage does not preclude the attending physician from providing treatment—if the patient can obtain other funding to pay for it.”); 02-1845 Pet. App. 177a; 03-83 Pet. App. 34a-35a. The fact that Section 502(a)(1)(B) provides remedies for the precise types of wrongs respondents allege confirms that respondents’ state-law claims fall within the scope of that provision and are therefore completely preempted.⁵

C. The Fact That Plaintiffs’ Actions Are Tort-Based Underscores Their Complete Preemption

1. The court of appeals held that respondents’ claims are not completely preempted—indeed, are not preempted at all—because the fact that they are tort-based makes their “claims of HMO medical malpractice differ fundamentally

710, 711-712 (W.D.N.Y. 1991) (similar); *White v. Caterpillar, Inc.*, 765 F. Supp. 1418, 1419-1420 (W.D. Mo.) (similar), aff’d, 985 F.2d 564 (8th Cir. 1991).

⁵ If, contrary to our argument, respondents’ state-court actions fell outside the scope of Section 502(a)(1)(B), they may nevertheless be completely preempted because they would fall within the scope of Section 502(a)(3) of ERISA, 29 U.S.C. 1132(a)(3). Section 502(a)(3) allows a participant or beneficiary to sue to enjoin a violation of ERISA or of the plan, or to obtain “other appropriate equitable relief” to redress such a violation or to enforce any provisions of ERISA or the plan. 29 U.S.C. 1132(a)(3). Section 502(a)(3) thus allows participants and beneficiaries to obtain individual relief for a breach of a fiduciary obligation. *Varity Corp. v. Howe*, 516 U.S. 489, 507-515 (1996). See also note 13, *infra*.

from * * * § 502(a)(1)(B) claims.” 02-1845 Pet. App. 16a. The court reasoned that “Section 502(a)(1)(B) * * * creates a cause of action for breach of contract,” while respondents “assert tort claims.” *Ibid.* The court went on to emphasize the remedies sought and noted that “Calad is not requesting the value of an extra night at the hospital, and Davila is not requesting reimbursement for the more expensive drug the HMO denied.” *Id.* at 17a. Because respondents “are not seeking reimbursement for benefits denied them,” *ibid.*, the court concluded that their claims are not preempted or completely preempted by Section 502(a)(1)(B).

The court’s conclusion is inconsistent with *Pilot Life, Taylor*, and *Ingersoll-Rand*, each of which involved claims that were directly pleaded as tort or tort-like claims and each of which involved claims for damages that extended beyond the benefits or rights due.⁶ In each of those cases, the Court held that the plaintiff’s claims were preempted, and nothing in the Court’s analysis or result suggested that the label placed upon the plaintiff’s claim in those cases—whether contract, tort, or some mixture of the two—had any relevance at all to the question. “Any other result would elevate form over substance and allow parties to evade the requirements of [the federal statute] by relabeling their contract claims as claims for tortious breach of contract.”

⁶ See *Pilot Life*, 481 U.S. at 43 (plaintiff pled claims for “Tortious Breach of Contract,” “Breach of Fiduciary Duties,” and “Fraud in the Inducement,” and sought compensatory and punitive damages); *Taylor*, 481 U.S. at 61, 62 (noting that plaintiff sought “compensation for mental anguish caused by breach of * * * contract” and holding that plaintiff’s “common law contract and tort claims are pre-empted by ERISA”); *Ingersoll-Rand*, 498 U.S. at 136 (Plaintiff “sought compensatory and punitive damages under various tort and contract theories.”); see also *Rush*, 536 U.S. at 377 (“In *Pilot Life*, an ERISA plan participant who had been denied benefits sued in a state court on state tort and contract claims.”); *id.* at 379 (noting that in *Ingersoll-Rand*, the court “had no trouble finding that Texas’s tort of wrongful discharge * * * conflicted with ERISA enforcement”).

Allis-Chalmers Corp. v. Lueck, 471 U.S. 202, 211 (1985) (holding that complete preemption under Section 301 of the LMRA, which provides for enforcement of contract rights under a collective bargaining agreement, applies to state-law tort claims). Indeed, the fact that the state-law claims provide additional tort-based remedies rather than merely duplicating the remedies typically available under Section 502(a)(1)(B) only underscores the rationale for finding those claims preempted. Although the labels placed on the plaintiffs' claims in *Pilot Life* and subsequent cases thus had no significance, the fact that the plaintiffs in those cases sought tort-like remedies that extended beyond those authorized in Section 502(a)(1)(B) was at the heart of the Court's conclusion that the claims conflicted with Congress's tailoring of remedies in ERISA and therefore were preempted or completely preempted.

2. The court of appeals recognized that *Pilot Life* "includes some expansive language" that "arguably supports" complete preemption, 02-1845 Pet. App. 19a, but the court believed that this Court's more recent decision in *Rush Prudential HMO, Inc. v. Moran*, 536 U.S. 355 (2002), "indicates that *Pilot Life* does not sweep so broadly." As support for that contention, the court of appeals noted that this Court in *Rush* had characterized *Ingersoll-Rand* as a case in which the "state law duplicated the elements of a claim available under ERISA" and had stated that the state law thus "converted the remedy from an equitable one under § 1132(a)(3) * * * into a legal one for money damages." 02-1845 Pet. App. 19a-20a (quoting *Rush*, 536 U.S. at 379). In the court of appeals' view, that reference in *Rush* generated a rule that "the test employed for 'complete preemption'" is that "States may not duplicate the causes of action listed in ERISA § 502(a)." *Id.* at 20a.

The court of appeals' reasoning is faulty. Nothing in *Rush* suggests that complete preemption is *limited* to such cases

of “duplication.” And in any event, the sense in which the claim in *Ingersoll-Rand* “duplicated” the ERISA cause of action is identical to the sense in which the claims in *Pilot Life*, *Taylor*, and this case do. As explained above, the plaintiff’s claim in each case “duplicate[s]” an ERISA claim because it cannot succeed without essentially proving the elements of an ERISA claim. The fact that the plaintiffs in *Ingersoll-Rand* and other cases prior to *Rush* might have had to prove *additional* facts or elements beyond those required by Section 502(a)(1)(B) or Section 502(a)(3) to obtain the additional forms of recovery they sought under state law did not prevent preemption of the state-law claims. It is typically true that a plaintiff seeking to recover compensatory or punitive damages must prove facts beyond those necessary to establish a violation of a substantive duty by the defendant. That aspect of the cases therefore was of no significance. What was significant was that, with respect to claims that required proof of the essential elements of an ERISA claim, state law provided for remedies beyond those available under ERISA, thus making the preemption of the state law particularly clear. See *Pilot Life*, 481 U.S. at 54-57; *Taylor*, 481 U.S. at 63, 64-65; *Ingersoll-Rand*, 498 U.S. at 144-145. Similarly here, the fact that respondents would have to prove additional facts or elements to obtain the compensatory and punitive damages they seek—remedies not available under Section 502(a)(1)(B)—does not prevent preemption of their state-law claims.

Far from casting doubt on those earlier precedents, this Court’s decision in *Rush* relied upon and reinforced them. The Court emphasized that the state statute providing for independent review of HMO medical necessity determinations in that case “provides no new cause of action under state law and authorizes no new form of ultimate relief.” 536 U.S. at 379. Because “the relief ultimately available [after the independent review] would still be what ERISA author-

izes in a suit for benefits under § 1132(a),” the Court explained that *Rush* “does not involve the sort of additional claim or remedy exemplified in *Pilot Life* [and] *Ingersoll-Rand*.” *Id.* at 380. On that basis, the Court held that the state-law independent-review scheme did not fall within *Pilot Life*’s rule of categorical preemption. *Ibid.* In this case, by contrast, respondents plainly do seek remedies beyond those provided by Section 502(a)(1)(B). Accordingly, the Court’s reasoning in *Rush* supports and reaffirms the conclusion that under *Pilot Life*, *Taylor*, and *Ingersoll-Rand*, respondents’ claims are completely preempted.

D. *Pegram v. Herdrich* Does Not Bar Complete Preemption Of Respondents’ Claims

The court of appeals suggested briefly that this Court’s concern in *Pegram v. Herdrich*, 530 U.S. 211 (2000), that “ERISA should not be interpreted to preempt state malpractice laws or to create a federal common law of medical malpractice” supports its conclusion that the state-law claims in this case are not completely preempted. 02-1845 Pet. App. 20a; see also *Cicio v. Does*, 321 F.3d 83, 100-104 (2d Cir. 2003), petition for cert. filed, No. 03-69 (July 11, 2003). That suggestion is mistaken.⁷

1. In *Pegram*, an ERISA plan participant contended that an HMO had violated its fiduciary duties under ERISA by structuring its operations so that its physician-owners re-

⁷ The court of appeals relied more extensively on *Pegram* for its conclusion that the claims here are not preempted by Section 502(a)(2) of ERISA, 29 U.S.C. 1132(a)(2). 02-1845 Pet. App. 12a-15a. That provision does not preempt respondents’ actions for reasons independent of *Pegram*. Section 502(a)(2) allows a participant or beneficiary to sue a fiduciary for “appropriate relief” under Section 409 of ERISA, 29 U.S.C. 1109, including “removal of [a breaching] fiduciary,” 29 U.S.C. 1109(a). Section 502(a)(2), however, provides relief to the plan, rather than to individuals. *Massachusetts Mut. Life Ins. Co. v. Russell*, 473 U.S. 134, 140 (1985). Because the claimants here seek only individual relief, their claims do not fall within the scope of Section 502(a)(2).

ceived greater profits if they held down the HMO's medical treatment expenses. The plaintiff alleged that the plan's physicians acted in a fiduciary capacity when they made "mixed eligibility and treatment decisions," 530 U.S. at 229—decisions that mix questions concerning "the plan's coverage of a particular condition or medical procedure for its treatment" with "choices about how to go about diagnosing and treating a patient's condition," *id.* at 228. This Court held that "mixed eligibility [and treatment] decisions by HMO physicians are not fiduciary decisions" that are subject to suit under Section 502(a)(2) for breach of a fiduciary duty under ERISA. *Id.* at 237.

2. *Pegram* is inapposite here. Even if HMO coverage decisions by a *non*-treating physician were "mixed" eligibility and treatment decisions under *Pegram* (but see pp. 23-25, *infra*), there would be no reason for the Court to read *Pegram* to foreclose complete preemption of respondents' state-law claims. The Court in *Pegram* stated that it was not addressing preemption issues. See 530 U.S. at 229 n.9. Moreover, this case does not turn on whether any particular decision was or was not a fiduciary decision under ERISA. It does not matter in this case whether the HMO representatives who decided not to pay for respondents' requested medical treatment made a fiduciary decision under ERISA or a "mixed" eligibility and treatment decision that was not a fiduciary act under *Pegram*. In either event, the state-law actions brought by respondents fall within the scope of Section 502(a)(1)(B) and seek to add to ERISA's remedies by permitting a plan participant to recover damages, including punitive damages, for a denial of benefits. A wrongful denial of benefits is actionable under Section 502(a)(1)(B) regardless of whether it constitutes a fiduciary breach. Accordingly, those state-law actions fall within the scope of Section 502(a)(1)(B), and are removable to federal court, regardless

of the fiduciary or non-fiduciary nature of the decisions attacked by respondents.

3. In any event, as the government pointed out in its brief as amicus curiae in *Rush*, *Pegram*'s holding that "mixed eligibility [and treatment] decisions by HMO physicians are not fiduciary decisions" under ERISA, 530 U.S. at 237, should not be extended beyond decisions made by treating physicians who are also making HMO eligibility decisions. See U.S. Br. at 7-11, *Rush*, *supra* (No. 00-1021). Although some statements in *Pegram*, if read in isolation, might suggest a broader application of the "non-fiduciary" rule, the better reading of *Pegram* is that it addresses only mixed decisions made by treating physicians.⁸

That limitation of *Pegram* to treating physicians serving dual roles makes sense. When the same doctor decides both treatment and eligibility questions, as may occur in a staff-model HMO, the treatment decision truly is "practically inextricable" from the eligibility decision. In HMOs such as those in this case, however, the treatment and coverage questions are separate, with a contract physician deciding the appropriate treatment and the HMO independently deciding whether to pay for it. The coverage decision may, as in *Pegram*, turn on a determination of medical necessity, but

⁸ The plaintiff's claim in *Pegram* grew out of a decision made by her treating physician, see 530 U.S. at 215, 217, 231, and there is no indication that she then sought review through the plan's appeal process. Furthermore, although the Court in *Pegram* did not regard the plaintiff's claim of fiduciary breach as limited to a single incident of poor treatment, see *id.* at 226, the Court did appear to view her claim as involving only an attack on the compensation policies as they affected treating physicians. See, e.g., *id.* at 228 (noting that treatment and eligibility decisions are "practically inextricable from one another * * * not merely because" they are "made by the same person, the *treating physician*," but also "because a great many * * * coverage questions are not simple yes-or-no questions") (emphasis added); *id.* at 232 ("physicians through whom HMOs act make just the sorts of decisions made by licensed medical practitioners millions of times every day").

in the end it is a decision on whether the HMO will pay under the terms of the plan, not whether the physician may provide the recommended treatment anyway (with some other source of funds) outside the plan. See *GAO Report 12* (a health plan’s decision to deny coverage does not preclude the attending physician from providing treatment if the patient can pay for it). Under the *Pegram* categorization, therefore, the HMO’s decision is an “eligibility” determination that is subject to ERISA fiduciary duty standards, not a “mixed” decision outside those standards.

Pegram also must be read against the background of provisions of ERISA itself and longstanding Labor Department regulations and interpretations that provide that plan administrators who make coverage decisions on review of the denials of claims for benefits *are* plan fiduciaries. Whatever else HMOs do to provide health care to the participants and beneficiaries of an ERISA plan they service, acting as the entity that determines eligibility for plan benefits in a given case is at the core of what HMOs do.⁹ ERISA makes clear that an entity responsible for that determination must be an ERISA fiduciary. See 29 U.S.C. 1002(21)(A)(iii) (a fiduciary includes a person to the extent “he has any discretionary authority or discretionary responsibility in the administration of such plan”); *Varsity Corp.*, 516 U.S. at 511 (“a plan

⁹ See *Pegram*, 530 U.S. at 219 (citations omitted):

At the least, HMOs, like traditional insurers, will in some fashion make coverage determinations, scrutinizing requested services against the contractual provisions to make sure that a request for care falls within the scope of covered circumstances (pregnancy, for example), or that a given treatment falls within the scope of the care promised (surgery, for instance). They customarily issue general guidelines for their physicians about appropriate levels of care. * * * And they commonly require utilization review (in which specific treatment decisions are reviewed by a decisionmaker other than the treating physician) and approval in advance (precertification) for many types of care, keyed to standards of medical necessity or the reasonableness of the proposed treatment.

administrator engages in a fiduciary act when making a discretionary determination about whether a claimant is entitled to benefits under the terms of the plan documents”); accord *id.* at 530 (Thomas, J., dissenting).¹⁰ Construing *Pegram* to mean that HMO representatives are not ERISA fiduciaries when they decide on behalf of the plan whether to pay for treatment that a primary care physician recommends would thus conflict with the statutory and administrative framework for claims adjudication generally.

E. Complete Preemption Effectuates The Congressional Balance Between Providing Prompt And Appropriate Remedies For Claimants And Encouraging The Formation And Growth of Employee Benefit Plans

ERISA does not provide the full range of remedies available under state tort law and does not provide at all for punitive damages. In some circumstances, moreover, a denial of coverage by an HMO may result in a denial of treatment—if time constraints effectively preclude a suit for injunctive relief under ERISA and the claimant cannot afford to pay for treatment from other funds and then later seek recovery from the HMO. Those features of ERISA’s enforcement scheme, however, do not mean that this Court should refuse to apply the complete preemption doctrine to HMO coverage decisions that may in turn have an effect on a claimant’s

¹⁰ See also 29 U.S.C. 1133(2) (“[i]n accordance with regulations of the Secretary [of Labor], every employee benefit plan shall * * * afford a reasonable opportunity to any participant whose claim for benefits has been denied for a full and fair review *by the appropriate named fiduciary* of the decision denying the claim”) (emphasis added). Section 503(2) also requires ERISA plans to decide claims “[i]n accordance with regulations of the Secretary.” 29 U.S.C. 1133(2). The Secretary has made clear that claimants must have an opportunity to appeal “an adverse benefit determination *to an appropriate named fiduciary.*” 29 C.F.R. 2560.503-1(h)(1) (emphasis added); see also 29 C.F.R. 2560.503-1(h)(3)(ii) and (i)(1)(ii); 29 C.F.R. 2560.503-1(g)(1) (2000) (superseded regulation, requiring appeal to fiduciary or person designated by the fiduciary).

ability to obtain medical treatment. Such a refusal would upset the balance reflected in ERISA’s civil enforcement provisions between providing prompt and appropriate remedies for claimants and encouraging the formation and growth of employee benefit plans.

1. In enacting ERISA, Congress intended generally to promote the interests of participants and beneficiaries in employee benefit plans, 29 U.S.C. 1001(b), but Congress stopped short of requiring employers to establish such plans. *Lockheed Corp. v. Spink*, 517 U.S. 882, 887 (1996). Congress also did not require employers that offer plans to “provide any particular benefits.” *Shaw v. Delta Air Lines, Inc.*, 463 U.S. 85, 91 (1983).¹¹ Accordingly, the “comprehensive civil enforcement scheme” in Section 502(a) of ERISA, 29 U.S.C. 1132(a), “represents a careful balancing of the need for prompt and fair claims settlement procedures against the public interest in encouraging the formation of employee benefit plans.” *Ingersoll-Rand*, 498 U.S. at 144 (quoting *Pilot Life*, 481 U.S. at 54).

The balance Congress struck provides effective remedies for most claimants who promptly and properly seek them.¹²

¹¹ One of the very few exceptions is 29 U.S.C. 1185(a), which requires group health plans and health insurance issuers to provide at least 48 hours of hospitalization after childbirth, if they offer maternity benefits. ERISA does not require minimum periods of hospitalization for other benefits a plan chooses to provide, such as coverage for respondent Calad’s hysterectomy.

¹² HMOs must provide claimants with “full and fair review” of a denial of a claim for benefits. 29 U.S.C. 1133(2); 29 C.F.R. 2560.503-1(h)(1). Such review must “take[] into account all comments, documents, records, and other information submitted by the claimant relating to the claim.” 29 C.F.R. 2560.503-1(h)(2)(iv). The plan administrator’s decision must also provide the “specific reasons” for any adverse determination (29 U.S.C. 1133(1); 29 C.F.R. 2560.503-1(g)(1)(i) and (j)(1)), and the claimant must be furnished, or afforded the right to obtain, an “explanation of the scientific or clinical judgment” for certain determinations by group health and disability plans. 29 C.F.R. 2560.503-1(j)(5)(ii). See generally U.S. Amicus Br.

First, under Section 502(a)(1)(B), Congress has allowed claimants to sue not just for benefits that are due, but also to enforce their rights under the plan and clarify rights to future benefits. 29 U.S.C. 1132(a)(1)(B). Thus, a claimant may bring an action under Section 502(a)(1)(B) to challenge a pre-treatment denial of coverage by asking a court to order a managed care company (or other entity that administers a health plan) to pay for proposed treatment. See note 4, *supra*. Successful claimants may be awarded attorneys' fees. See 29 U.S.C. 1132(g). District courts have been able to act quickly to provide relief to such claimants when necessary. See, e.g., *Wilson v. Group Hospitalization & Med. Servs., Inc.*, 791 F. Supp. 309, 310 (D.D.C. 1992) (April 13, 1992 temporary restraining order prevented insurer from refusing to pay for April 14, 1992 treatment), appeal dismissed, 995 F.2d 306 (D.C. Cir. 1993); *White v. Caterpillar, Inc.*, 765 F. Supp. 1418, 1418-1419 (W.D. Mo.) (action brought June 13, 1991; preliminary injunction issued June 26, 1991), *aff'd*, 985 F.2d 564 (8th Cir. 1991). Further remedies may also be available under Section 502(a)(3) of ERISA, which provides, *inter alia*, for "appropriate equitable relief" to "redress" violations of ERISA (including its fiduciary-duty provisions, see *Varity Corp.*, 516 U.S. at 507-515) or of an ERISA plan.¹³

at 8-11, 15-17, *Black & Decker Disability Plan v. Nord*, 538 U.S. 822 (2003) (No. 02-469).

¹³ Although this Court has construed Section 502(a)(3) not to authorize an award of money damages against a non-fiduciary, it has also recognized that the "equitable relief" authorized by Section 502(a)(3) means relief typically available in equity. See *Great-West Life & Annuity Ins. Co. v. Knudson*, 534 U.S. 204, 210, 217 (2002); *Mertens v. Hewitt Assocs.*, 508 U.S. 248, 248-250, 256-258 (1993). Neither *Great-West* nor *Mertens* involved actions against a fiduciary. After *Great-West*, the government has taken the position in several cases pending in the courts of appeals that Section 502(a)(3) allows at least some forms of "make-whole" relief against a breaching fiduciary in light of the general availability of such relief in equity at the time of the divided bench. See generally Sec'y of Labor Amicus Br. at 19-23, *Mathews v. Chevron Corp.*, Nos. 02-15936 & 02-16209

Second, Congress required plans to establish a claims procedure in accordance with regulations of the Secretary of Labor. 29 U.S.C. 1133. The Department of Labor’s new claims regulations, applicable to plan years beginning July 1, 2002, see 66 Fed. Reg. 35,886 (2001), specifically address managed care decision-making by including short time frames for a group health plan’s decisions on claims. See 29 C.F.R. 2560.503-1(f)(2)(i) (decision no later than 72 hours after receipt of claim for urgent care claims); 29 C.F.R. 2560.503-1(f)(2)(iii)(A) (not later than 15 days for a pre-service claim, subject to one extension for matters beyond plan’s control). Those new regulations may reduce the need for and incidence of court challenges. See *Pryzbowski v. U.S. Healthcare, Inc.*, 245 F.3d 266, 275 (3d Cir. 2001).

Third, States may provide for an independent review of HMO medical necessity decisions. *Rush*, 536 U.S. at 359-360.

(9th Cir. filed Nov. 25, 2002). Historically, a beneficiary’s claim against a trustee for a breach of trust was typically remedied *exclusively* in the courts of equity because the beneficiary had only an equitable, not a legal interest, in the trust and its assets. See Restatement (Second) of the Law of Trusts §§ 2 cmts. e and f, 197 (1959). A beneficiary therefore could maintain a suit in equity to obtain various forms of relief, including to compel the trustee to perform his duties as trustee, to enjoin the trustee from committing a breach, and “to compel the trustee to redress a breach of trust.” *Id.* § 199(a)-(c). The trustee’s liability in the event of a breach gave rise to various alternative remedies, including a remedy that “will put [the beneficiary] in the position in which he would have been if the trustee had not committed the breach of trust.” *Id.* § 205 & cmt. a. A monetary recovery in those circumstances did not require a showing of unjust enrichment. See, e.g., *id.* § 205, cmt. c; *Strom v. Goldman, Sachs & Co.*, 202 F.3d 138 (2d Cir. 1999); *Bowerman v. Wal-Mart Stores, Inc.*, 226 F.3d 574 (7th Cir. 2000); see generally George G. Bogert & George T. Bogert, *The Law of Trusts and Trustees* 861, at 3-4 (rev. 2d ed. 1995). Neither *Great-West* nor *Mertens* supports the proposition that Congress intended that the courts should ignore that settled trust-law understanding dating from the days of the divided bench. There is no occasion for the Court to address that issue here. Judicial acceptance of this position would, however, provide an effective remedy in many cases where the remedy under Section 502(a)(1)(B) may be inadequate.

Such review also decreases the chances that a claimant will be harmed by an erroneous HMO coverage decision. See *GAO Report 24* (external review procedure “could resolve disputes before harm occurred and could prevent the need for lawsuits later on”); Gail B. Agrawal & Mark A. Hall, *What If You Could Sue Your HMO? Managed Care Liability Beyond the ERISA Shield*, 47 *St. Louis U. L.J.* 235, 278 (2003).

Finally, claimants may also sue their treating physicians for malpractice if the physicians’ actions of commission or omission fall below the standards set for appropriate medical care. See, e.g., *Pryzbowski*, 245 F.3d at 279. Courts have also held that HMOs may be sued under state law, without preemption by ERISA, when they are vicariously liable for a treating physician’s decisions. See, e.g., *In re U.S. Healthcare, Inc.*, 193 F.3d 151, 162 (3d Cir. 1999), cert. denied, 530 U.S. 1242 (2000); *Villazon v. Prudential Health Care Plan, Inc.*, 843 So. 2d 842, 851-854 (Fla. 2003). In addition, HMOs like petitioner Aetna and CIGNA in this case have an incentive to inform participants clearly that they provide only coverage, not treatment, and that an HMO determination not to provide coverage does not preclude claimants from obtaining care recommended by a treating physician through other sources of funds.

2. Failing to find preemption of state remedies would “completely undermine[]” Congress’s decision to include certain remedies and exclude others under ERISA itself. *Ingersoll-Rand*, 498 U.S. at 144 (quoting *Pilot Life*, 481 U.S. at 54). As employers have noted, imposition of liability under state law could prevent employers from designing innovative health plans that are consistent across state borders and could make employers less willing to provide health benefits because of the higher costs associated with them. *GAO Report 22*; see also *id.* at 27. That result would

frustrate ERISA's broader goal of promoting the interests of participants and beneficiaries.

Indeed, permitting such suits against HMOs that provide health care through ERISA plans could easily lead to large punitive damage awards—something that ERISA itself, with its tailored remedies, does not allow. See *Dardinger v. Anthem Blue Cross & Blue Shield*, 781 N.E.2d 121, 140-145 (Ohio 2002) (\$30 million punitive damage award); Gail B. Agrawal & Mark A. Hall, *supra*, 47 St. Louis U. L.J. at 240 n.16 (reporting punitive damage awards of \$77 million and \$120 million, and an award of \$80 million that was set aside on appeal for improper jury instructions and evidentiary errors). There is nothing in ERISA or in this Court's precedents that requires such a result.

CONCLUSION

The judgment of the court of appeals should be reversed.

Respectfully submitted.

HOWARD M. RADZELY
Solicitor of Labor

ALLEN H. FELDMAN
Associate Solicitor

NATHANIEL I. SPILLER
Deputy Associate Solicitor

EDWARD D. SIEGER
Attorney
Department of Labor

PAUL D. CLEMENT

*Acting Solicitor General**

EDWIN S. KNEEDLER

Deputy Solicitor General

JAMES A. FELDMAN

Assistant to the Solicitor
General

DECEMBER 2003

* The Solicitor General is recused in this case.